An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation

Trial Profile

An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs ODN/Pam2 (Primary)
  • Indications Pneumocystis pneumonia
  • Focus Therapeutic Use
  • Sponsors Pulmotect
  • Most Recent Events

    • 08 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
    • 08 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.
    • 08 Aug 2017 Planned initiation date changed from 1 Apr 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top